Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Iradimed (IRMD) over the last 12 years, with Q3 2025 value amounting to -$50236.0.

  • Iradimed's Asset Writedowns and Impairment fell 15156.32% to -$50236.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$379800.0, marking a year-over-year decrease of 29931.88%. This contributed to the annual value of -$94535.0 for FY2024, which is 14537.6% down from last year.
  • According to the latest figures from Q3 2025, Iradimed's Asset Writedowns and Impairment is -$50236.0, which was down 15156.32% from $4829.0 recorded in Q2 2025.
  • In the past 5 years, Iradimed's Asset Writedowns and Impairment ranged from a high of $180788.0 in Q1 2023 and a low of -$296675.0 during Q4 2024
  • Its 5-year average for Asset Writedowns and Impairment is $13245.3, with a median of $12254.0 in 2022.
  • As far as peak fluctuations go, Iradimed's Asset Writedowns and Impairment surged by 288652.77% in 2022, and later crashed by 245952.89% in 2024.
  • Over the past 5 years, Iradimed's Asset Writedowns and Impairment (Quarter) stood at $66486.0 in 2021, then fell by 29.84% to $46649.0 in 2022, then tumbled by 124.85% to -$11591.0 in 2023, then tumbled by 2459.53% to -$296675.0 in 2024, then skyrocketed by 83.07% to -$50236.0 in 2025.
  • Its Asset Writedowns and Impairment stands at -$50236.0 for Q3 2025, versus $4829.0 for Q2 2025 and -$37718.0 for Q1 2025.